Articles

Two for TRP inhibitors

Boehringer Ingelheim and Hydra Biosciences strike a collaboration to identify TRP inhibitors for the treatment of renal diseases
Written byKelsey Kaustinen
| 2 min read

CAMBRIDGE, Mass. & INGELHEIM, Germany—Hydra Biosciences Inc., which specializes in the field of transient receptor potential (TRP) channel modulation, has announced a worldwide research collaboration and license agreement with Boehringer Ingelheim under which the companies will work together for the identification of small-molecule TRP inhibitors. The initial focus will be on the treatment of renal diseases and disorders.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.